Sort   by:  
 Page size 
UnknownPhase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Not available
S-EPMC3454772 | biostudies-literature
UnknownPhase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
Not available
S-EPMC5455684 | biostudies-literature
TranscriptomicsComparative Genomics of D. ethenogenes 195 and an Unsequenced Dehalococcoides-Containing Enrichment Culture
Tetrachloroethene (PCE) and trichloroethene (TCE) are prevalent groundwater contaminants that can be completely reductively dehalogenated by Dehalococcoides organisms. A Dehalococcoides-containing microbial consortium (ANAS) with the ability to degrade TCE to ethene, an innocuous end-product, was pr...
ORGANISM(S): Dehalobacter restrictus 
2010-06-20 | E-GEOD-9612 | biostudies-arrayexpress
UnknownDoes increased implementation support improve community clinics' guideline-concordant care? Results of a mixed methods, pragmatic comparative effectiveness trial.
Not available
S-EPMC6894475 | biostudies-literature
UnknownEffect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Not available
S-EPMC8176388 | biostudies-literature
TranscriptomicsRecurrent disruption of HIP1 identified in patients with epilepsy, learning difficulties, intellectual disability, and neurobehavioral abnormalities
We report 12 individuals from ten unrelated families with epilepsy, learning difficulties, intellectual disability, and neurobehavioral abnormalities, who segregated a microdeletion distally adjacent to the Williams-Beuren syndrome region. In six families, a recurrent ~ 1.1 Mb deletion likely result...
ORGANISM(S): Homo sapiens 
2010-08-28 | E-GEOD-23834 | biostudies-arrayexpress
UnknownAdd-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Not available
S-EPMC12120674 | biostudies-literature
Sort   by:  
 Page size